Wellington Management Group LLP Has $60.83 Million Holdings in Integra LifeSciences Holdings Corporation $IART

Key Points

• Wellington Management Group LLP increased its stake in Integra LifeSciences by 10.4%, now holding approximately 2.77 million shares valued at $60.83 million.
• Integra LifeSciences reported Q2 earnings per share of $0.45, exceeding estimates, despite revenue declining 0.6% year-over-year.
• Most brokerage analysts have reduced their price targets for Integra LifeSciences, with a consensus rating of "Reduce" and an average price target of $18.63.

Wellington Management Group LLP lifted its position in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 10.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,766,125 shares of the life sciences company's stock after acquiring an additional 259,987 shares during the quarter. Wellington Management Group LLP owned approximately 3.56% of Integra LifeSciences worth $60,827,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the company. Assenagon Asset Management S.A. lifted its position in shares of Integra LifeSciences by 2,418.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock valued at $39,581,000 after acquiring an additional 1,728,480 shares in the last quarter. Paradigm Capital Management Inc. NY lifted its position in shares of Integra LifeSciences by 170.3% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock valued at $32,457,000 after acquiring an additional 901,600 shares in the last quarter. Lord Abbett & CO. LLC lifted its position in shares of Integra LifeSciences by 86.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company's stock valued at $30,210,000 after acquiring an additional 618,773 shares in the last quarter. Soleus Capital Management L.P. purchased a new stake in shares of Integra LifeSciences in the 4th quarter valued at approximately $28,940,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Integra LifeSciences by 9.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,146,921 shares of the life sciences company's stock valued at $25,221,000 after acquiring an additional 99,348 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company's stock.

Integra LifeSciences Stock Down 1.7%

Shares of Integra LifeSciences stock traded down $0.26 during midday trading on Thursday, reaching $14.61. 178,764 shares of the company's stock traded hands, compared to its average volume of 1,038,710. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -2.21, a price-to-earnings-growth ratio of 0.83 and a beta of 1.16. The company's 50 day simple moving average is $12.92 and its 200 day simple moving average is $16.23. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. Integra LifeSciences Holdings Corporation has a 52 week low of $11.06 and a 52 week high of $27.13.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.02. The business had revenue of $415.61 million for the quarter, compared to the consensus estimate of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. Integra LifeSciences's revenue for the quarter was down .6% on a year-over-year basis. During the same quarter last year, the firm earned $0.63 EPS. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Equities analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. cut their target price on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. JMP Securities cut their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Finally, Wells Fargo & Company cut their target price on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and four have given a Sell rating to the company's stock. According to MarketBeat, Integra LifeSciences presently has a consensus rating of "Reduce" and a consensus target price of $18.43.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.